

GenCore version 4.5
Copyright (c) 1993 - 1998 Compugen Ltd.
OM protein - protein search, using sw. model
Run on: January 25, 2000, 03:59:51 ; Search time 29.27 seconds
(w/o alignments) updates/sec
546.229 Million cell

Title: US-09-332-063-2
Perfect score: 3347
Sequence: 1 MERAQQSSASYQPVPADE\.....KPIQIOLGQEPAENWVLL 675

Scoring table: BLOSUM62
Seq-hed: 188963 seqs, 23686:06 residues

Da se: A_Geneset_35; *
Word size : 0

Number of hits that pass the threshold : 188963
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	229.5	6.9	783	1 W37151	Mouse neural Mena+ Mouse neural Mena+ Mouse neural Mena+ Human mitosin. Pur. Human mitosin amin Kinesin core protein Trypanosoma cruzi Smooth muscle myosin T. cruzi L19E homo Human ALP. New nuc Nucleolar/endosoma Human mblA. Rho tar Streptococcus uber Rattus norvegicus GAL4/HA/NUMA fusions LexA/NUMA fusion p Antigen tc-7a. vac AMML chromosome in AMML chromosome in AMML chromosome in Sequence of the in Protein with Rho p Mouse Rho target p Mouse mblA Rho tar Drosophila sp. Cos Protein with Rho P HSV-2 strain SB5 C Restin protein seq MSF precursor. New Strep-tococcus pneu K39 polypeptide of Leishmania chagasi Human 160kD mediat TMF. New protein C M. tuberculosis RP Mycobacterium tube Mycobacterium tube Human NonO/FEE3 fu Streptococcus pneu
2	229	6.8	802	1 W37153	
3	228.5	6.8	787	1 W37152	
4	226.5	6.8	2482	1 W372825	
5	226.5	6.8	2482	1 W23996	
6	226	6.7	3248	1 W23995	
7	216	6.5	442	1 W26540	
8	213	6.4	1972	1 W00024	
9	212.5	6.3	262	1 W06924	
10	212.5	6.3	1274	1 W89253	
11	211	6.3	1411	1 W02258	
12	209.5	6.3	1315	1 W76733	
13	207.5	6.2	561	1 W63043	
14	205.5	6.1	576	1 W54241	
15	204	6.1	2272	1 W21732	
16	204	6.1	180	1 R22393	
17	203	6.1	61	1 R66929	
18	203	6.1	885	1 R66930	
19	203	6.1	816	1 R66931	
20	203	6.1	2101	1 R47173	
21	201.5	6.0	199	1 W56475	
22	199.5	6.0	1388	1 W56475	
23	199	5.9	1255	1 W52249	
24	198	5.9	1201	1 W90345	
25	197.5	5.9	1372	1 W56473	
26	197.5	5.9	3119	1 W72204	
27	197	5.9	1392	1 Y05919	
28	195.5	5.9	194	1 R26049	
29	194	5.8	206	1 W14574	
30	193.5	5.8	955	1 R57365	
31	193.5	5.8	955	1 W03691	
32	193.5	5.7	1427	1 R10534	
33	191	5.7	1093	1 R42818	
34	191	5.7	1907	1 W95400	
35	190.5	5.7	763	1 W31855	
36	190	5.7	572	1 W52629	
37	188.5	5.6	188	1 W14593	
38	188	5.6	929	1 W14593	

RESULT
W37151
I: W37151 standard; Protein: 783 AA.
AC: W37151;
DT: 06-JUL-1993 (first entry)
DE: Mouse natural Mena+ protein.
KW: Neural Mena+ protein; mammalian Ena; Enabled protein; Evl protein; cytoskeleton; cell morphology; cell adhesion; cell differentiation; cell growth; cell motility; mouse.
OS: Mus musculus.
OU: MUSCULUS.
FH: Location/Qualifiers
FT: Misc-difference /note= "encoded by G3P"
FD: 15-JUN-1998.
PR: 05-JUL-1996; US-675815.
PA: (GB3) GES BIOTECHNOLOGISCHE FORSCHUNG MBH.
PA: (HJTC-) HUTCHINSON CANCER RES CENT FRED.
PA: Gerlier FB, Niebuhr K, Soriano P, Weiland J;
DR: WPI; 98-101197/09.
D2: N-PSJB; V02998
D3: Detection of modulators of Mena and Ena-VASP-like genes and proteins
D4: - used in control of cytoskeletal dynamic events in normal and abnormal cell morphology, adhesion, motility, growth and differentiation
D5: P5: Uniprot: P35861
CC: This protein comprises novel murine neural Mena+. Its amino acid sequence was deduced from a cDNA clone (see V02998) obtained from a mouse brain cDNA library. Neural Mena+ contains an exon that introduces 244 amino acids between amino acids 238 and 239 of mammalian Ena (Mena, see W37148). Two other isoforms, neural Mena+ (see W37152), and neural Mena++ (see W37153), are also disclosed. Unlike Mena, neural Mena isoforms exhibit neural tissue-specific distribution. Based on the disclosed Mena and Evl genes (see also V02996-97) and proteins (see also W37148-49), a variety of methods and compositions are provided for screening, isolating and characterising endogenous and exogenous factors, drugs and therapeutic agents useful to evaluate and/or control cytoskeletal dynamic events involved in normal and abnormal cell morphology, adhesion, motility, growth and/or differentiation. A method of detecting a modulator of Mena activity/expression is claimed.
D6: CC: Sequence
D7: CC: Sequence
D8: CC: Sequence
D9: CC: Sequence
D10: CC: Sequence
D11: CC: Sequence
D12: CC: Sequence
D13: CC: Sequence
D14: CC: Sequence
D15: CC: Sequence
D16: CC: Sequence
D17: CC: Sequence
D18: CC: Sequence
D19: CC: Sequence
D20: CC: Sequence
D21: CC: Sequence
D22: CC: Sequence
D23: CC: Sequence
D24: CC: Sequence
D25: CC: Sequence
D26: CC: Sequence
D27: CC: Sequence
D28: CC: Sequence
D29: CC: Sequence
D30: CC: Sequence
D31: CC: Sequence
D32: CC: Sequence
D33: CC: Sequence
D34: CC: Sequence
D35: CC: Sequence
D36: CC: Sequence
D37: CC: Sequence
D38: CC: Sequence
D39: CC: Sequence
D40: CC: Sequence
D41: CC: Sequence
D42: CC: Sequence
D43: CC: Sequence
D44: CC: Sequence
D45: CC: Sequence
D46: CC: Sequence
D47: CC: Sequence
D48: CC: Sequence
D49: CC: Sequence
D50: CC: Sequence
D51: CC: Sequence
D52: CC: Sequence
D53: CC: Sequence
D54: CC: Sequence
D55: CC: Sequence
D56: CC: Sequence
D57: CC: Sequence
D58: CC: Sequence
D59: CC: Sequence
D60: CC: Sequence
D61: CC: Sequence
D62: CC: Sequence
D63: CC: Sequence
D64: CC: Sequence
D65: CC: Sequence
D66: CC: Sequence
D67: CC: Sequence
D68: CC: Sequence
D69: CC: Sequence
D70: CC: Sequence
D71: CC: Sequence
D72: CC: Sequence
D73: CC: Sequence
D74: CC: Sequence
D75: CC: Sequence
D76: CC: Sequence
D77: CC: Sequence
D78: CC: Sequence
D79: CC: Sequence
D80: CC: Sequence
D81: CC: Sequence
D82: CC: Sequence
D83: CC: Sequence
D84: CC: Sequence
D85: CC: Sequence
D86: CC: Sequence
D87: CC: Sequence
D88: CC: Sequence
D89: CC: Sequence
D90: CC: Sequence
D91: CC: Sequence
D92: CC: Sequence
D93: CC: Sequence
D94: CC: Sequence
D95: CC: Sequence
D96: CC: Sequence
D97: CC: Sequence
D98: CC: Sequence
D99: CC: Sequence
D100: CC: Sequence
D101: CC: Sequence
D102: CC: Sequence
D103: CC: Sequence
D104: CC: Sequence
D105: CC: Sequence
D106: CC: Sequence
D107: CC: Sequence
D108: CC: Sequence
D109: CC: Sequence
D110: CC: Sequence
D111: CC: Sequence
D112: CC: Sequence
D113: CC: Sequence
D114: CC: Sequence
D115: CC: Sequence
D116: CC: Sequence
D117: CC: Sequence
D118: CC: Sequence
D119: CC: Sequence
D120: CC: Sequence
D121: CC: Sequence
D122: CC: Sequence
D123: CC: Sequence
D124: CC: Sequence
D125: CC: Sequence
D126: CC: Sequence
D127: CC: Sequence
D128: CC: Sequence
D129: CC: Sequence
D130: CC: Sequence
D131: CC: Sequence
D132: CC: Sequence
D133: CC: Sequence
D134: CC: Sequence
D135: CC: Sequence
D136: CC: Sequence
D137: CC: Sequence
D138: CC: Sequence
D139: CC: Sequence
D140: CC: Sequence
D141: CC: Sequence
D142: CC: Sequence
D143: CC: Sequence
D144: CC: Sequence
D145: CC: Sequence
D146: CC: Sequence
D147: CC: Sequence
D148: CC: Sequence
D149: CC: Sequence
D150: CC: Sequence
D151: CC: Sequence
D152: CC: Sequence
D153: CC: Sequence
D154: CC: Sequence
D155: CC: Sequence
D156: CC: Sequence
D157: CC: Sequence
D158: CC: Sequence
D159: CC: Sequence
D160: CC: Sequence
D161: CC: Sequence
D162: CC: Sequence
D163: CC: Sequence
D164: CC: Sequence
D165: CC: Sequence
D166: CC: Sequence
D167: CC: Sequence
D168: CC: Sequence
D169: CC: Sequence
D170: CC: Sequence
D171: CC: Sequence
D172: CC: Sequence
D173: CC: Sequence
D174: CC: Sequence
D175: CC: Sequence
D176: CC: Sequence
D177: CC: Sequence
D178: CC: Sequence
D179: CC: Sequence
D180: CC: Sequence
D181: CC: Sequence
D182: CC: Sequence
D183: CC: Sequence
D184: CC: Sequence
D185: CC: Sequence
D186: CC: Sequence
D187: CC: Sequence
D188: CC: Sequence
D189: CC: Sequence
D190: CC: Sequence
D191: CC: Sequence
D192: CC: Sequence
D193: CC: Sequence
D194: CC: Sequence
D195: CC: Sequence
D196: CC: Sequence
D197: CC: Sequence
D198: CC: Sequence
D199: CC: Sequence
D200: CC: Sequence
D201: CC: Sequence
D202: CC: Sequence
D203: CC: Sequence
D204: CC: Sequence
D205: CC: Sequence
D206: CC: Sequence
D207: CC: Sequence
D208: CC: Sequence
D209: CC: Sequence
D210: CC: Sequence
D211: CC: Sequence
D212: CC: Sequence
D213: CC: Sequence
D214: CC: Sequence
D215: CC: Sequence
D216: CC: Sequence
D217: CC: Sequence
D218: CC: Sequence
D219: CC: Sequence
D220: CC: Sequence
D221: CC: Sequence
D222: CC: Sequence
D223: CC: Sequence
D224: CC: Sequence
D225: CC: Sequence
D226: CC: Sequence
D227: CC: Sequence
D228: CC: Sequence
D229: CC: Sequence
D230: CC: Sequence
D231: CC: Sequence
D232: CC: Sequence
D233: CC: Sequence
D234: CC: Sequence
D235: CC: Sequence
D236: CC: Sequence
D237: CC: Sequence
D238: CC: Sequence
D239: CC: Sequence
D240: CC: Sequence
D241: CC: Sequence
D242: CC: Sequence
D243: CC: Sequence
D244: CC: Sequence
D245: CC: Sequence
D246: CC: Sequence
D247: CC: Sequence
D248: CC: Sequence
D249: CC: Sequence
D250: CC: Sequence
D251: CC: Sequence
D252: CC: Sequence
D253: CC: Sequence
D254: CC: Sequence
D255: CC: Sequence
D256: CC: Sequence
D257: CC: Sequence
D258: CC: Sequence
D259: CC: Sequence
D260: CC: Sequence
D261: CC: Sequence
D262: CC: Sequence
D263: CC: Sequence
D264: CC: Sequence
D265: CC: Sequence
D266: CC: Sequence
D267: CC: Sequence
D268: CC: Sequence
D269: CC: Sequence
D270: CC: Sequence
D271: CC: Sequence
D272: CC: Sequence
D273: CC: Sequence
D274: CC: Sequence
D275: CC: Sequence
D276: CC: Sequence
D277: CC: Sequence
D278: CC: Sequence
D279: CC: Sequence
D280: CC: Sequence
D281: CC: Sequence
D282: CC: Sequence
D283: CC: Sequence
D284: CC: Sequence
D285: CC: Sequence
D286: CC: Sequence
D287: CC: Sequence
D288: CC: Sequence
D289: CC: Sequence
D290: CC: Sequence
D291: CC: Sequence
D292: CC: Sequence
D293: CC: Sequence
D294: CC: Sequence
D295: CC: Sequence
D296: CC: Sequence
D297: CC: Sequence
D298: CC: Sequence
D299: CC: Sequence
D300: CC: Sequence
D301: CC: Sequence
D302: CC: Sequence
D303: CC: Sequence
D304: CC: Sequence
D305: CC: Sequence
D306: CC: Sequence
D307: CC: Sequence
D308: CC: Sequence
D309: CC: Sequence
D310: CC: Sequence
D311: CC: Sequence
D312: CC: Sequence
D313: CC: Sequence
D314: CC: Sequence
D315: CC: Sequence
D316: CC: Sequence
D317: CC: Sequence
D318: CC: Sequence
D319: CC: Sequence
D320: CC: Sequence
D321: CC: Sequence
D322: CC: Sequence
D323: CC: Sequence
D324: CC: Sequence
D325: CC: Sequence
D326: CC: Sequence
D327: CC: Sequence
D328: CC: Sequence
D329: CC: Sequence
D330: CC: Sequence
D331: CC: Sequence
D332: CC: Sequence
D333: CC: Sequence
D334: CC: Sequence
D335: CC: Sequence
D336: CC: Sequence
D337: CC: Sequence
D338: CC: Sequence
D339: CC: Sequence
D340: CC: Sequence
D341: CC: Sequence
D342: CC: Sequence
D343: CC: Sequence
D344: CC: Sequence
D345: CC: Sequence
D346: CC: Sequence
D347: CC: Sequence
D348: CC: Sequence
D349: CC: Sequence
D350: CC: Sequence
D351: CC: Sequence
D352: CC: Sequence
D353: CC: Sequence
D354: CC: Sequence
D355: CC: Sequence
D356: CC: Sequence
D357: CC: Sequence
D358: CC: Sequence
D359: CC: Sequence
D360: CC: Sequence
D361: CC: Sequence
D362: CC: Sequence
D363: CC: Sequence
D364: CC: Sequence
D365: CC: Sequence
D366: CC: Sequence
D367: CC: Sequence
D368: CC: Sequence
D369: CC: Sequence
D370: CC: Sequence
D371: CC: Sequence
D372: CC: Sequence
D373: CC: Sequence
D374: CC: Sequence
D375: CC: Sequence
D376: CC: Sequence
D377: CC: Sequence
D378: CC: Sequence
D379: CC: Sequence
D380: CC: Sequence
D381: CC: Sequence
D382: CC: Sequence
D383: CC: Sequence
D384: CC: Sequence
D385: CC: Sequence
D386: CC: Sequence
D387: CC: Sequence
D388: CC: Sequence
D389: CC: Sequence
D390: CC: Sequence
D391: CC: Sequence
D392: CC: Sequence
D393: CC: Sequence
D394: CC: Sequence
D395: CC: Sequence
D396: CC: Sequence
D397: CC: Sequence
D398: CC: Sequence
D399: CC: Sequence
D400: CC: Sequence
D401: CC: Sequence
D402: CC: Sequence
D403: CC: Sequence
D404: CC: Sequence
D405: CC: Sequence
D406: CC: Sequence
D407: CC: Sequence
D408: CC: Sequence
D409: CC: Sequence
D410: CC: Sequence
D411: CC: Sequence
D412: CC: Sequence
D413: CC: Sequence
D414: CC: Sequence
D415: CC: Sequence
D416: CC: Sequence
D417: CC: Sequence
D418: CC: Sequence
D419: CC: Sequence
D420: CC: Sequence
D421: CC: Sequence
D422: CC: Sequence
D423: CC: Sequence
D424: CC: Sequence
D425: CC: Sequence
D426: CC: Sequence
D427: CC: Sequence
D428: CC: Sequence
D429: CC: Sequence
D430: CC: Sequence
D431: CC: Sequence
D432: CC: Sequence
D433: CC: Sequence
D434: CC: Sequence
D435: CC: Sequence
D436: CC: Sequence
D437: CC: Sequence
D438: CC: Sequence
D439: CC: Sequence
D440: CC: Sequence
D441: CC: Sequence
D442: CC: Sequence
D443: CC: Sequence
D444: CC: Sequence
D445: CC: Sequence
D446: CC: Sequence
D447: CC: Sequence
D448: CC: Sequence
D449: CC: Sequence
D450: CC: Sequence
D451: CC: Sequence
D452: CC: Sequence
D453: CC: Sequence
D454: CC: Sequence
D455: CC: Sequence
D456: CC: Sequence
D457: CC: Sequence
D458: CC: Sequence
D459: CC: Sequence
D460: CC: Sequence
D461: CC: Sequence
D462: CC: Sequence
D463: CC: Sequence
D464: CC: Sequence
D465: CC: Sequence
D466: CC: Sequence
D467: CC: Sequence
D468: CC: Sequence
D469: CC: Sequence
D470: CC: Sequence
D471: CC: Sequence
D472: CC: Sequence
D473: CC: Sequence
D474: CC: Sequence
D475: CC: Sequence
D476: CC: Sequence
D477: CC: Sequence
D478: CC: Sequence
D479: CC: Sequence
D480: CC: Sequence
D481: CC: Sequence
D482: CC: Sequence
D483: CC: Sequence
D484: CC: Sequence
D485: CC: Sequence
D486: CC: Sequence
D487: CC: Sequence
D488: CC: Sequence
D489: CC: Sequence
D490: CC: Sequence
D491: CC: Sequence
D492: CC: Sequence
D493: CC: Sequence
D494: CC: Sequence
D495: CC: Sequence
D496: CC: Sequence
D497: CC: Sequence
D498: CC: Sequence
D499: CC: Sequence
D500: CC: Sequence
D501: CC: Sequence
D502: CC: Sequence
D503: CC: Sequence
D504: CC: Sequence
D505: CC: Sequence
D506: CC: Sequence
D507: CC: Sequence
D508: CC: Sequence
D509: CC: Sequence
D510: CC: Sequence
D511: CC: Sequence
D512: CC: Sequence
D513: CC: Sequence
D514: CC: Sequence
D515: CC: Sequence
D516: CC: Sequence
D517: CC: Sequence
D518: CC: Sequence
D519: CC: Sequence
D520: CC: Sequence
D521: CC: Sequence
D522: CC: Sequence
D523: CC: Sequence
D524: CC: Sequence
D525: CC: Sequence
D526: CC: Sequence
D527: CC: Sequence
D528: CC: Sequence
D529: CC: Sequence
D530: CC: Sequence
D531: CC: Sequence
D532: CC: Sequence
D533: CC: Sequence
D534: CC: Sequence
D535: CC: Sequence
D536: CC: Sequence
D537: CC: Sequence
D538: CC: Sequence
D539: CC: Sequence
D540: CC: Sequence
D541: CC: Sequence
D542: CC: Sequence
D543: CC: Sequence
D544: CC: Sequence
D545: CC: Sequence
D546: CC: Sequence
D547: CC: Sequence
D548: CC: Sequence
D549: CC: Sequence
D550: CC: Sequence
D551: CC: Sequence
D552: CC: Sequence
D553: CC: Sequence
D554: CC: Sequence
D555: CC: Sequence
D556: CC: Sequence
D557: CC: Sequence
D558: CC: Sequence
D559: CC: Sequence
D560: CC: Sequence
D561: CC: Sequence
D562: CC: Sequence
D563: CC: Sequence
D564: CC: Sequence
D565: CC: Sequence
D566: CC: Sequence
D567: CC: Sequence
D568: CC: Sequence
D569: CC: Sequence
D570: CC: Sequence
D571: CC: Sequence
D572: CC: Sequence
D573: CC: Sequence
D574: CC: Sequence
D575: CC: Sequence
D576: CC: Sequence
D577: CC: Sequence
D578: CC: Sequence
D579: CC: Sequence
D580: CC: Sequence
D581: CC: Sequence
D582: CC: Sequence
D583: CC: Sequence
D584: CC: Sequence
D585: CC: Sequence
D586: CC: Sequence
D587: CC: Sequence
D588: CC: Sequence
D589: CC: Sequence
D590: CC: Sequence
D591: CC: Sequence
D592: CC: Sequence
D593: CC: Sequence
D594: CC: Sequence
D595: CC: Sequence
D596: CC: Sequence
D597: CC: Sequence
D598: CC: Sequence
D599: CC: Sequence
D600: CC: Sequence
D601: CC: Sequence
D602: CC: Sequence
D603: CC: Sequence
D604: CC: Sequence
D605: CC: Sequence
D606: CC: Sequence
D607: CC: Sequence
D608: CC: Sequence
D609: CC: Sequence
D610: CC: Sequence
D611: CC: Sequence
D612: CC: Sequence
D613: CC: Sequence
D614: CC: Sequence
D615: CC: Sequence
D616: CC: Sequence
D617: CC: Sequence
D618: CC: Sequence
D619: CC: Sequence
D620: CC: Sequence
D621: CC: Sequence
D622: CC: Sequence
D623: CC: Sequence
D624: CC: Sequence
D625: CC: Sequence
D626: CC: Sequence
D627: CC: Sequence
D628: CC: Sequence
D629: CC: Sequence
D630: CC: Sequence
D631: CC: Sequence
D632: CC: Sequence
D633: CC: Sequence
D634: CC: Sequence
D635: CC: Sequence
D636: CC: Sequence
D637: CC: Sequence
D638: CC: Sequence
D639: CC: Sequence
D640: CC: Sequence
D641: CC: Sequence
D642: CC: Sequence
D643: CC: Sequence
D644: CC: Sequence
D645: CC: Sequence
D646: CC: Sequence
D647: CC: Sequence
D648: CC: Sequence
D649: CC: Sequence
D650: CC: Sequence
D651: CC: Sequence
D652: CC: Sequence
D653: CC: Sequence
D654: CC: Sequence
D655: CC: Sequence
D656: CC: Sequence
D657: CC: Sequence
D658: CC: Sequence
D659: CC: Sequence
D660: CC: Sequence
D661: CC: Sequence
D662: CC: Sequence
D663: CC: Sequence
D664: CC: Sequence
D665: CC: Sequence
D666: CC: Sequence
D667: CC: Sequence
D668: CC: Sequence
D669: CC: Sequence
D670: CC: Sequence
D671: CC: Sequence
D672: CC: Sequence
D673: CC: Sequence
D674: CC: Sequence
D675: CC: Sequence
D676: CC: Sequence
D677: CC: Sequence
D678: CC: Sequence
D679: CC: Sequence
D680: CC: Sequence
D681: CC: Sequence
D682: CC: Sequence
D683: CC: Sequence
D684: CC: Sequence
D685: CC: Sequence
D686: CC: Sequence
D687: CC: Sequence
D688: CC: Sequence
D689: CC: Sequence
D690: CC: Sequence
D691: CC: Sequence
D692: CC: Sequence
D693: CC: Sequence
D694: CC: Sequence
D695: CC: Sequence
D696: CC: Sequence
D697: CC: Sequence
D698: CC: Sequence
D699: CC: Sequence
D700: CC: Sequence
D701: CC: Sequence
D702: CC: Sequence
D703: CC: Sequence
D704: CC: Sequence
D705: CC: Sequence
D706: CC: Sequence
D707: CC: Sequence
D708: CC: Sequence
D709: CC: Sequence
D710: CC: Sequence
D711: CC: Sequence
D712: CC: Sequence
D713: CC: Sequence
D714: CC: Sequence
D715: CC: Sequence
D716: CC: Sequence
D717: CC: Sequence
D718: CC: Sequence
D719: CC: Sequence
D720: CC: Sequence
D721: CC: Sequence
D722: CC: Sequence
D723: CC: Sequence
D724: CC: Sequence
D725: CC: Sequence
D726: CC: Sequence
D727: CC: Sequence
D728: CC: Sequence
D729: CC: Sequence
D730: CC: Sequence
D731: CC: Sequence
D732: CC: Sequence
D733: CC: Sequence
D734: CC: Sequence
D735: CC: Sequence
D736: CC: Sequence
D737: CC: Sequence
D738: CC: Sequence
D739: CC: Sequence
D740: CC: Sequence
D741: CC: Sequence
D742: CC: Sequence
D743: CC: Sequence
D744: CC: Sequence
D745: CC: Sequence
D746: CC: Sequence
D747: CC: Sequence
D748: CC: Sequence
D749: CC: Sequence
D750: CC: Sequence
D751: CC: Sequence
D752: CC: Sequence
D753: CC: Sequence
D754: CC: Sequence
D755: CC: Sequence
D756: CC: Sequence
D757: CC: Sequence
D758: CC: Sequence
D759: CC: Sequence
D760: CC: Sequence
D761: CC: Sequence
D762: CC: Sequence
D763: CC: Sequence
D764: CC: Sequence
D765: CC: Sequence
D766: CC: Sequence
D767: CC: Sequence
D768: CC: Sequence
D769: CC: Sequence
D770: CC: Sequence
D771: CC: Sequence
D772: CC: Sequence
D773: CC: Sequence
D774: CC: Sequence
D775: CC: Sequence
D776: CC: Sequence
D777: CC

QY 276 YLEENVMRHEALDAATVAAQDITVISHSPNTSYDTALEARIKEEERELMANKRCLDM 335
 | :
 Db 233 RRMNSNAAPSSDSSLSSAASLPEYSSCOPPSAAPPSSYAVISAPVDATP----- 283
 QY 336 EGRIKTLHQIIEKDAMKVLOORSRKRPSKTEQLSCMRPA--KSLMSISNAGGGLSHS 393
 | :
 Db 283 -----AVITAL-----PTSTPPTPPLRHAATRFRATLSIGSAHHPVILPH 321
 QY 394 STLGSPIEKKERDKSWKGSLLGILGGDYRAEVVPSTP----- 433
 | :
 Db 322 ATVP-RPLKNSR-----PSSPVNTPSSQPAAKSCAWPTSNF 358
 QY 433 SPVPPSTLASH--SKTGSRCSTQERGTISNKTAAVAPSVPVAAAATAITA 489
 ||| :
 359 SPLIPSPMIMSSPKATGP-----PVLPVCVSSVPQMPPPS--TA 400
 QY 490 TAATITTMVAAPAVAAAD-----AAAAPSP 520
 | :
 Db 401 PNCSDLSDTYPVSPPTSGPAAPPPPPPPPPLPPPLPLASLSHCGSQAAPP 460
 QI 521 ATAAATAAVSPAAQOIPAASVASAVAVAP-----SAAAAAVQVAPAPVAP 573
 | :
 Db 461 GTPLASTPSSKPSV--LPSPSAGAPASAETPLNPELGDSASEPGLQAA-SQPAESPTP 516
 QY 574 -ALV--EVVAPAAQOASAQOQAPASAPAVAPVAPTPAFTPTPVAQAEVVASPAVGPPH 629
 ||| :
 Db 517 QGLVLGPPARPPPPPLPSGPAY-----ASALPPPGSPPPPPL--PSTGPPP 562
 QY 630 RLSIPSLTCNPDKTDGP-----VFHSNTLERKTP 659
 | :
 Db 563 PPPPPPL--PNQAPPPPPPPPLPRLPASGIFSGSTSEDNRPL 602

RESULT 2
 W7153 ID W37153 standard; Protein; 802 AA.
 AC W7153; 06-JUL-1998 (first entry)
 DT DE Mouse neural Men+ protein.
 KW Neural Men+ protein; mammalian Ena; Enabled protein; Evl protein;
 cytoskeleton; cell morphology; cell adhesion; cell differentiation;
 cell growth; cell motility; mouse.
 OS Mus musculus.
 PN W09801755-A1.
 PD 15-JAN-1998.
 PR PF 03-JUL-1997; U11669.
 PR 05-JUL-1996; US-675815.
 PA (GBFB) GES BIOTECHNOLOGISCHE FORSCHUNG MBH.
 PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
 PT -AUTC-) HUTCHINSON CANCER RES CENT FRED.
 PI DR Gertler FB, Niebuhr K, Soriano P, Wehland J;
 WPI; 98-101197/09.
 PT Detection of modulators of Mena and Ena-VASP-like genes and proteins
 used in control of cytoskeletal dynamic events in normal and
 abnormal cell morphology, adhesion, motility, growth and
 differentiation.

Example 4, Page 63-55; 77pp; English.
 This protein comprises novel murine neural Men++. Its amino acid sequence was deduced from a cDNA clone obtained from a mouse brain cDNA library. Two other isoforms, neural Mena+ (see W37151) and neural Mena++ (see W37152), are also disclosed. Unlike mammalian Ena (Mena, see W37148), neural Mena isoforms exhibit neural tissue-specific distribution. Based on the disclosed Mena and Evl genes (see also W02996-98) and proteins (see also W37149-49), a variety of methods and compositions are provided for screening, isolating and characterising endogenous and exogenous factors, drugs and therapeutic agents useful to evaluate and/or control cytoskeletal dynamic events involved in normal and abnormal cell morphology, adhesion, motility, growth and/or differentiation. A method of detecting a modulator of Mena activity/expression is claimed.

Sequence 802 AA;

Query Match 6.8%; Score 229; DB 1; Length 802;
 Best Local Similarity 20.4%; Pred. No. 1 7e-05;
 Matches 134; Conservative 89; Mismatches 205; Indels 228; Gaps 28;

QY 98 FNKDLRERLETTANKO-LAEKEYEGSEDR-----KTISOLFA-KNKSOREK 142
 | :
 Db 100 FASAMMHAEVINSQEAQSKVYATODSTNLRCIFCGPTLPRQPAQONGPQEEEL 159
 QY 143 EKLEAELATARSTNEODORRHIERDOALSNAQAVVKEELKKQVVDVERMOALV 202
 | :
 Db 160 ETORROL-----QEQQRQKLEREDMERELERLERLERBLER-----ERLEOE-- 204
 QY 203 QIAQACERKQELEFLRURLELESRLIQORQNGOPTNVEYNAALMILREKEERI 262
 ||| :
 Db 204 QLERQRERHVERLERLERL-ERER-QRE-----RERL 238
 QY 263 LAEADMTWKWCKYLEENVMRHEALDAATVAAQDITVISHSPNTSYDTALEARIKEE 322
 | :
 Db 239 EQLEREQEWEVERRNSNAAPSSDSSLSSAALPVEYSSCOPPSAAPPSSYAVISAPVDAT 298
 QY 323 EELMANKRCLDMEGRIKTLHQIIEKDAMKVLOORSRKRPSKTEQLSCMRPA--KSLM 380
 | :
 Db 299 RDY-----AVITAL-----PTSTPPTPPLRHAATRFRAT 327
 QY 381 SISNASSGGLLSSISSTLGSPIEKKERDKSWKGSLLGILGGDYRAEVVPSP----- 433
 | :
 Db 328 SLGSAFHIVPLPHIATV-PPLKNSR-----PSSPVNTPSSQ 364
 QY 433 SPVPPSTLASH--SKTGSRCSTQERGTISNKTAAVAPSVP----- 476
 | :
 Db 365 PAKSCAWPTNSFSPSPVSPIMISPPGKATGP-----PVLPVCSS 408
 QY 477 PYAAATAATAATATAATITTMVAAPAVAAAD----- 513
 | :
 Db 409 PVQOMPPSP-TAPNSLDSTYVSPSPPSGAPAPPPLPPPLPPPLPPPLA 466
 QY 513 -----AAAABSPATATAATAAVSPAAQOIPAASVASAVAVP-----SAAAAAV 560
 | :
 Db 467 SLSHCGSQASPPPGTPLASLPSKPSV--LPSPSAGAPASAETPLNPELGDSASEPGL 523
 QY 561 QVAPAPAPVAPV-ALV--EVVAPAAQOASAQOQAPASAPAVAPVTPAFTPTPVAQA 616
 | :
 Db 524 QKA-SQPAESTPQGIVLGPAPPPLPPPLPSGPAY-----ASALPPPPRPPPPPL-- 574
 QY 617 EVPASATGPGPHRLSIPSCTCNPDKTDGP-----VFHSNTLERKTP 659
 | :
 Db 574 -----PSTGPPPPIPPL--PNQAPPPPPPAPPLPASGIFSGSTSEDNRPL 621

RESULT 3
 W37152 ID W37152 standard; Protein; 787 AA.
 AC W37152; 06-JUL-1998 (first entry)
 DE Mouse neural Men+ protein.

KW Neural Men+ protein; mammalian Ena; Enabled protein; cell skeleton; cell morphology; cell adhesion; cell differentiation; cell growth; cell motility; mouse.

OS Mus musculus.
 PN W09801755-A1.
 PD 15-JAN-1998.
 PR 03-JUL-1997; U11669.
 PR 05-JUL-1996; US-675815.
 PA (GBFB) GES BIOTECHNOLOGISCHE FORSCHUNG MBH.
 PA (HUTC-) HUTCHINSON CANCER RES CENT FRED.
 PI DR Gertler FB, Niebuhr K, Soriano P, Wehland J;
 WPI; 98-101197/09.
 PT Detection of modulators of Mena and Ena-VASP-like genes and proteins used in control of cytoskeletal dynamic events in normal and abnormal cell morphology, adhesion, motility, growth and differentiation.

Example 4; Page 60-63; 77pp; English.
 This protein comprises novel murine neural Men++. Its amino acid

QY 457 TERGESNKTAAVATISRAVPAATAAATATI-TTVAAPAVAAAPAA 514
 CC can also be used for the detection and diagnosis of hyperproliferative
 SQ cells.
 Sequence 2482 AA;

RESULT 5
 Db 2338 DTEGTE----FEPEGLPEVKKGFDADIPTGKTSPIYLRTTM----- 2376
 ID W23996 standard; Protein; 2482 AA;
 AC W23996;
 DT 28-MAY-1998 (first entry)
 DE human mitosin amino acid sequence.
 KF itosin; phosphoprotein; mitotic cell cycle; antibody; analogue; inhibition; M phase; Antagonist; hyperproliferative cell; cancer; leukaemia; lymphoma; chromosome segregation.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT Domains 258. .280
 /note= "leucine heptad repeat"
 FT Domain 340. .362
 FT Domain 564. .593
 FT Domain 1387. .1443
 FT Domain 1885. .1962
 FT Domain 2146. .2188
 FT Domain 2165. .2187
 FT Misc_difference 2188 /note= "leucine heptad repeat"
 FT Misc_difference 2300 /label= "Bipartite targeting motif"
 FT /note= "Optionaly C or G"
 FT Misc_difference 2301
 FT Misc_difference 2303 /label= "Bipartite targeting motif"
 FT /note= "opinaly A or T"
 PN US51710022-A.
 PD 20-JAN-1998.
 PF 24-OCT-1994; 328254.
 PR 24-OCT-1994; US-328254.
 PR -22-OCT-1993; US-141230.
 PR (X) UNIV TEXAS SYSTEM.
 PI Jee W, Zhu X;
 DR WPI; 98-10817/10.

PT New isolated mitosin protein and gene - useful for, e.g. developing products for therapy and diagnosis of hyper-proliferative disorders such as cancers or psoriasis

PS Claim 1; Column 40-52; 43PP; English.
 This is the amino acid sequence for mitosin, a phosphoprotein necessary for the cell to enter mitosis. The protein's degradation is also necessary for the cell to advance into the next stages of mitosis. The mitosin protein, can be used to control the growth of cells. An anti-mitosin antibody, a mutant or a non-functional analogue of mitosin can inhibit the mitotic cell cycle by preventing the cells from entering the M phase, and over expression of mitosin or its functional equivalent, would inhibit the cycle by preventing cells from leaving the M phase. Antagonists to this protein can be used to control hyperproliferative cells in, (e.g. thyroid hyperplasia, Grave's disease, psoriasis, benign prostatic hypertrophy, Li-Fraumeni syndrome, breast cancer, sarcomas and other neoplasms, bladder cancer, colon cancer, lung cancer and various leukaemias and lymphomas). Reintroduction or supplementation of lost mitosin function by introduction of the protein or nucleic acid encoding the protein into a cell can restore defective chromosome segregation, which is a marker of progressing malignancy. Malignant proliferation of cells can then be halted. The protein

RESULT 6
 R99795 standard; Protein; 3248 AA.
 ID R99795
 AC R99795;
 DT 08-OCT-1996 (first entry)
 DE Kinetochore protein, CENP-F
 KW Kinetochore protein, CENP-F; cell cycle; cancer; diagnosis; autoimmune antibody.
 OS Homo sapiens.
 FH Key Location/Qualifiers
 FT domain 1. 200
 /label= Extended_coiled_structure
 FT domain 280. .1350
 /label= Extende_coiled_structure
 FT domain 1380. .1610
 /label= Globular_domain
 /label= "globular domain consists of 2 direct repeats of 95 amino acids"

Query Match 6.8%; Score 226.5; DB 1; Length 2482;
 Best Local Similarity 21.4%; Pred. No. 1e-05; Mismatches 233; Indels 179; Gaps 2
 Matches 139; Conservative 100; MisMatches 233; Indels 179; Gaps 2
 Db 2376 ATTRSP-RLAQKALPLSPLIGKENLAES----SKPTAGGSRSOKVQAORSPVDSGT 2428
 QY 515 AAAASPATAATAAVSPAAGQTPRASAAYASAAYAVAPAAVAPAPVAPA 574
 LVPYPAPAAQASAAQTOQAPTSADAVAPTPATPTPAVQAEVSPATG 625
 Db 2429 ILREP---TTKSPV---NNLPERSPIDSPREGLRVKRGRLVSPKAG 2470
 QY 79 ALEKAMRNKUKEGEIRRMHD-----FNRLREKLETANKQLAKEKEYEGSED- 124
 Db 2006 EL-SGCKNRLLAGELOLEEIKSSKDQLKELTLENSEKLSLDCMKDVKOEGKVREI 2064
 QY 124 -----TRKTSQLFANKNESOREKEKLEATATARSTNEORRHET--RDOAL 170
 Db 2055 AEYQURLHEAEKKHQALLNTNQKVEIQTREKLTSEKECLSSOKLEIDLKSSKEEL 2124
 QY 171 SNAQKVVKLEELKKQV---YVDKV---EKMQALVQLOACKECRELEHRURTRL 222
 Db 2125 NNSLAKTQOLLEELKTKMDNLKVNKLKNERAQGKMKLIKCKQLEEEKEELQKEL 2184
 QY 223 ERELBSLRIOOROGNCQPTINSEYVA -AALMELIREKEERILALBADMTWQEQLIEEN 280
 Db 2185 S-QLQAAQEKTGTWMDTKVDELTTEIKELKETLEEK-----TKEADEVLDKY 2232
 QY 281 VMRHFLDAATAVVAQDTAVISHSPNTSYDTALARIKEEEETIMANKRCIDMBGRK 340
 Db 2233 C-----SLISHE-----KLERAKEM-----LETQVA 2254
 QY 341 TLHAQIIEKDA---MIKVQORSRKEPSKTEQLSCMRPAKSLMSISNAGSSLHSSTL 396
 Db 2255 HLCSDQSKQDSRGSHLGPVPGPGRSPISI 11
 QY 397 TGSPIMEKRDKSXKGSLGLLGDYRAEVPSPTSPVPSIPLISAHSKTGSRDCSTO 456
 Db 2307 -----WENG---GG-----PTPATPEFSKSKKAVMSJTHPAE 2337
 QY 457 TERGESNKTAAVATISRAVPAATAAATATI-TTVAAPAVAAAPAA 514
 Db 2338 DTEGTE----FEPEGLPEVKKGFDADIPTGKTSPIYLRTTM----- 2376
 QY 515 AAAASPATAATAAVSPAAGQTPRASAAYASAAYAVAPAAVAPAPVAPA 574
 Db 2376 ATTRSP-RLAQKALPLSPLIGKENLAES----SKPTAGGSRSOKVQAORSPVDSGT 2428
 QY 575 LVPYPAPAAQASAAQTOQAPTSADAVAPTPATPTPAVQAEVSPATG 625
 Db 2429 ILREP---TTKSPV---NNLPERSPIDSPREGLRVKRGRLVSPKAG 2470

DR
PT
PT a vector for gene therapy for reduction of re-stenosis following
PT coronary artery catheterisation
PS Claim 5; Page 14-27; 42pp; Japanese.
CC This sequence represents the smooth muscle myosin heavy chain SML isoform
CC protein. The SML coding sequence was isolated from a mouse embryo cDNA
CC library using probes based on the rabbit smooth muscle myosin heavy chain
CC SM2 isoform. The isolated coding sequence is included in the gene
CC therapy vector of the invention. The vector of the invention consists of
CC the coding sequence inserted into a retrovirus, adenovirus, associated
CC adenovirus or animal-expression plasmid vector (such as pCXN2 or
CC PAGE20B). The vector can be used in the gene therapy treatment of
CC arteriosclerosis, particularly for the reduction of restenosis occurring
CC following coronary artery catheterisation for widening of sclerotic
SQ arteries.
Sequence 1972 AA:

PA
CORI-X CORIX CORP.
PI: Reed SG;
DR: WPI: 96-485445/48.
N-PSDB: T46148.
PT: Detecting and preventing *T. cruzi* infection - using polypeptide(s) of *T. cruzi*
PT or antibodies contg. or reactive with antigen epitope(s) of *T. cruzi*
PT proteins.
PS: Claim 1; Fig 2; 59pp; English.
CC The 35 kDa *T. cruzi* TCE antigen (W06913) shows homology in its
CC N-terminal portion to the eukaryotic ribosomal protein L1E. The
CC C-terminal portion comprises a 7-amino acid repeat region. The
CC TCE amino acid sequence was deduced from a cDNA clone (T46148)
CC isolated from an amastigote library. Epitopes such as TCE^{RR}
CC (W06914) derived from the TCE repeat region can be used in methods
CC for detecting *T. cruzi* infection (Chagas' disease) and in vaccine
CC compns. Polypeptides comprising the L1E homologous region can be
CC used in methods for detecting *Leishmania* or *T. cruzi* infection.
Sequence 262 AA;

	Local Similarity	Score	DB	Length	Indels	Gaps	Mismatches
QY	0.4%	21.3	1	1972	14;		
Db	0.4%	21.7%	5.1e-05				
QY	86; Conservative	85;					
Db	1554	DVQATEDAKLREVNMQALKQFEDQLQARDNEEKRRQLOKHLHETELEDERKORA	1613	79			
QY	80	LEKAMENKLLEGIRRHMDFNRDLRERLETANQOLAE	1614	--KEYEGS-BDTKTIQSFLA	133		
Db	1614	LAAAKKKLEGDLKDLELQADSAIKGKREBAIKOLRKIQAMDFORELDABASRDEFLA	1673				
QY	134	KNKESEOR-----EKELEBLATA--RSTNDORRH	162				
Db	1674	TSKENERKAKSLEADMLOQEDLAAERARKQADLEKEELABELASSLGSRLQDKEKR	1733				
QY	163	IEIRDQALNSQAQVKVLEEKKKQVYDKV-EKMQOALVQOACEKREOLEHRTR	221				
Db	1734	LE-----ARIAOLEEELEEQCNMAMSDRVKRATQ-----AEUSNELAT	1776				
QY	222	LERELESLRQORQNGOPTNVSEYNAAALMPLREKEERILALEADMTKWQKYLEN	281				
Db	1776	-ER-----STAQKNESRAROOLERONKE-----	1797				
QY	282	MRHFALDAATVAACQDTTIVSHSPNTSYDIALEARIKKEEEI-----LMANKRCLD	334				
Db	1797	LSKLOVEGAVAKAKLKSTV-----RALEAKTAQLEEQVEBARQOAATSKHQ	1846				
QY	335	MEGRKTLHQIIEKDMKVLQQRSRKEPSKTEOL	370				
Db	347	KDKKVEVLLQVEDERKMAEYQEOKGKNTVKOL	182				

ID WO6913 standard; Protein: 262 AA.
 AC WO6913;
 DT 02-APR-1997 (first entry)
 DE T. cruzi LiGE homologue "tce".
 KW LiGE homologue; TcE; diagnosis; infection; antigen; Chagas disease;
 leishmaniasis.
 OS Trypanosoma cruzi strain NHOM/CH/00/Tulahuen.
 Key Location/Qualifiers
 FH Location
 FT region
 FT 1..143
 FT /note= "Polypeptides comprising amino acids 1-143
 are useful in methods for screening for T.
 cruzi and Leishmania infection"
 FT 137..247
 FT /note= "Amino acids 137-247 comprise 15 copies of
 a tandemly arrayed 7-amino acid repeat."
 PN WO9629605-A2.
 PD 26-SEP-1996.
 PF 12-MAR-1996; UO3380.
 PR 14-MAR-1995; US-403379.

pathways that involve the proteins, particularly cancer (e.g. leukaemia and lymphoma), while modulators of ALK-7 (which is a type I receptor serine/threonine kinase) are used to promote neuronal survival, particularly for treating Alzheimer's, Parkinson's or Huntington's diseases. Nucleic acid fragments of the polynucleotides encoding the proteins can be used as probes to identify and clone related sequences; to detect protein-encoded RNA; to generate transgenic animals and in gene therapy (optionally after mutation). Ab are used to determine the proteins. CC (optionally after mutation). Ab are used to determine the Sequence 1274 AA;

SQ

Sequence 1274 AA;

Query Match 6.3%; Score 212.5; DB 1; Length 1274;
Best local similarity 20.7%; Pred. No. 3.1e-05;
Matches 151; Conservative 104; Mismatches 306; Indels 167; Gaps 30;
Pred. No. 3.1e-05;
Pfam ID: 3 AHEAASSLYSEKEAKKLREMAKTDKNEVLDQFDMSQDLPETWDNUBAYSHIPQLMEK 62
Qy 83 -----AMRN-----KLEGIRRMRMDFNRRLERELTANKQLAEKEYESSEDTRKT 127
Db 63 CAALSVRDTVRNLYQSMQVLGSGVFTDVASLKDIRLLE--EDELLEQKFQ----EA 114
Qy 128 ISOLFAKKRKESEKEKLEAELA-----TANSTNEQRKHEIR-----DQA 169
Db 115 VQQAGAISITSKAHLAVERREWAKYMEHEKAFTNSELHRMNLHYGNRLISGPQDQV 174
Qy 170 LSNRQAKVVKLEELKKKVQYDVKVEKQHQALVQLQAACEKRQEQLEHRLTRLEFESL 229
Db 175 RAALPPTPLSPEDKA-----VLOQNJKRLLAKVQEARQDVSQLEQQLRELIQKD--- 223
Qy 230 RIOORQGNCQPIINVSEYNAALMELREERELIALEADMTHQE---KYLEENWMRIFL 287
Db 223 -----DITASLWITDHSEMKKL-FEQLKKYDQLKVYLEQNLAAODRV 264
Qy 288 DAAT-----VAQDITVISHSPNTSYDT-----ALEARIQKEEEILMANKRCLDM 335
Db 265 LQALTEANVOYAVRRVLSLDQWNSTLQTLYAASYEAYEDLNKKSQE---GRDFYADL 320.
Qy 336 ESRKITL-----HQIIEKAMIKVLUQQRSKERPSKTSQLSCHRSQPKSLSM 381
Db 321 ESKVALLERTOSTCQAREARQQLLRE-----LKKKPPRPTAPKPLLPRESEAVE 375
Qy 382 ISNAGSLGLSHSSTLTGSPIMPERKDDKSWKSSKGIGLIGGDRAYEVUPSTSPVSPSTL 441
Db 376 AGDPPERLSLPPDMVAGPRLPD----TFLGS-----ATPLAHFPSPSPFST-- 419
Qy 442 LSAHKSGRSDCSTOTRGTEENKTAVALPISVAPPA-----AAATAAATATATITTMV 499
Db 419 ---GPGPHYLSPGLPPGTYSQPTQLIQP-RAPGHAMPVAPGPALYPAPAYTPEGLV 472
Qy 500 AAAPPVAVAAAPAAPAAPSPATAATAAASPAAGQI-----PAAVASASAAYAPSA 554
Db 473 PRSSPOHGIVSSPVYGVGPPAVGLSAPPQFSGELAMAVRPPATTVDISIQAPIPSH 532
Qy 555 AA---AAAVOVAPAAAPAPVAPALVVPAPRAAQASAPAO---TQAPTS--APAVAPT 604
Db 533 TAPPRPNTPAPRPPCFVPPVPPQPLPPTYPAKAGKOPIPAQOHFFSSGIGPTGPAPRIGQ 592
Qy 605 PAPTPMPAVADAEVAPASPATGPPHRISIPSLTCNPDKTQDPVFSNTLERKTPQ--- 661
Db 593 POPHPQPHPSQAFGQPPQO---PLPLQHPLF--PPOAPG-----LLPPQSPVYAPO 641
Qy 661 --ILGQEP 666
Db 642 PGVLGQPP 649

Query Match 6.3%; Score 211; DB 1; Length 1411;
Best local similarity 22.2%; Pred. No. 4.4e-05;
Matches 108; Conservative 75; Mismatches 155; Indels 148; Gaps 17;
Pred. No. 4.4e-05;
Pfam ID: 30 ELSDEN--RNURQELGSCYKEVARKWVJLQURSERENUVKSSKREALEKAMRK 87
Qy 528 FSVSKKNQIATQHLQKDLDCQHQSLASSETSLHRIH---VELSEGEATOKULEL 381
Db 83 LECEIRRMHDNDRERERELTANKQLAEKEYESSEDTRKTTSOLFANKRKESEKEKLEA 147
Db 382 SEVETKOH-----LKEFKDQLOQREKEEKGLO-LQSENINQHSLLERBOLGEAHG 435
Qy 148 ELATARSTNEORRHETIRDODALSNAQAKVVKLEELKK-----QVYVDKVERM-- 198
Db 436 KUKEOROLSEK---LMDKEQOVDLQKLRSLEEQKEVNTSTELQHOLDKTKQHOE 492
Qy 198 QQLVQQA---CEKREQUELRI-----OPT-----NYSEYNAALMEL-----TRLELESL-R 230
Db 493 QDQLOSTTAKLREAONDEQYLRQIDGKDQDKTIONLEALLOKSKENISLLEKEREDEVYK 552
Qy 231 IOQRQNC-----OPT-----NYSEYNAALMEL-----LREK 258
Db 553 TOAGESTAVINQLOQKNHTI-QEQVQFOLTERKNOSESHKQAEQNLHDQVQEKAHLRA 612
Qy 259 EERILALEADMT-----KWKQYLUENVMRFALDAATAQQR----- 298
Db 613 ODRVLSLETSYNELNSOLNESEKVSQOLDQIOTAKKTELLESEAAKTAORDLNLDTA 672
Qy 298 -----DTWVISHSPNTSIDABARICKEEEILMANKRCLDMERI 339
Db 673 ONALDQKQELNKITTOLDQWAKLQDKQEIQSLESHLKEYKVKYLSQKCTELEGQI 732
Qy 340 KTLHQACIE---KDMKIVQQRSR-----KEPSKEQLCMRPA 376
Db 733 KMLEAUSLEVASKSFGQALQDQQRQQLNTDEL RATELSQDLEMEREKIVSSISTRDQKS 792
Qy 377 RSLMSI 382
Db 793 PALESI 798

RESULT 12
WT;J34
ID W76734 standard; Protein: 1315 AA.
AC W76734; 1315 (first entry)
DT 09-MAR-1997 (first entry)
DE Nucleolar/endosomal auto-antigen p162.
KW Auto antibody; P162; rheumatic disease; antigen; diagnosis;
gene therapy.
CC Homo sapiens.
PN DE19515514 C1.
PD 12-SEP-1996.
PT 27-APR-1995; DE-015514.
PS (PRIV-) PRIVATE INST IMMUNOLOGIE & MOLEKULARGEN.
PA Renz M Seelig HP;
NP;I; 96 403153/41.
DR N-PDB; T58751.
PT DNA encoding nucleolar-endosomal auto-antigen - useful for exact diagnosis of rheumatic disease, in gene therapy and for removal of specific auto-antibodies
PS Claim 1; Fig 2; 15pp; German.
CC Transformed cells can be cultured to produce the antigen p162, for use in exact (different) diagnosis of rheumatic disease, i.e. they can detect, in immunoassays, Western blots, etc., rheumatism-specific auto-antibodies. The antigen can be used therapeutically, coupled to a cytotoxin, the elimination of auto-antibody-producing lymphocytes.
CC Sequence 1411 AA;

Human mDia Rho targeting protein.
 Rho Protein; mDia; mammalian diaphanous; target protein; human;
 rho protein-combining; Proline-combining; chromosome 5q31.2; disease;
 respiratory tract; overensitivity; bronchial asthma; marrow leukaemia;
 marrow dysplasia syndrome.
 Homo sapiens.
 J10202680-A.
 06-OCT-1998.
 25-MAR-1997; 090170.
 25-MAR-1997; JP-090170.
 (KIRI) KIRIN BREWERY KK.
 WPI; 99-002481/01.
 N-PSDB; V62933.
 Human Rho target protein and its gene - useful for elucidation of
 mechanisms of respiratory tract disease.
 Claim 1: Page 28-31; 5app; Japanese.
 This sequence represents a human Rho target protein, mDia (mammalian
 diaphanous). This protein has active type Rho protein-combining ability,
 has proline-combining ability has a MW. of 150 kDa measured by sodium
 dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and its
 gene is positioned at human chromosome 5q31.2. The nucleic acid can be
 used for the recombinant production of the protein. The protein is useful
 for the elucidation of mechanism of diseases such as respiratory tract
 oversensitivity, bronchial asthma, acute marrow leukaemia and marrow
 dysplasia syndrome.
 Sequence 1315 AA;

Query Match	6.3%	Score	209.5	DB	1	Length	1315
Best Local Similarity	20.5%	Pred.	No.	5e-05		Mismatches	280
Matches	163	Conservative				Indels	257
						Gaps	39
7	SASQYQPVP-ADPPFAIVRRAQQVY--ETLSDENR-----LQELECGYEK 49						
114	SSASYGDDPTTAQSLOQDVSDEQVLVLFQEMQLDNLNEEKQOPREKDIKKRMEVSOQLY 173						
50	VARIQKVETEIQRVESEAYENVLW-----SKREALEKAMN-----K 87						
174	TSKAGMSQKESSKSAMMYIODELSGLRDMPLUSCLESLRVSLNNPVSQWOTFFGAEGLAS 233						
88	LEGIRRMDFNRLRERLETANKQLAKEKEYESEDIFK-----TISQFLAKKNKESOREK 142						
234	LIDITKLKD-----EEATA-----GSYDSNKHLIRCKAFANNKG---- 274						
143	EKLAEELATARSTNEDORRHETRDQALNSAQAKVVKL-----EEELKK----- 188						
274	-----IKMLETBEGILLVLRAMPVNPNMMDAALKLISALCILPOPEDMNREVLEAMT 327						
188	-QVYZDVKYEVKMQDAL-----VOLQAC-----ERKSCOLEHLRTLE----- 224						
328	ERAEMDEVERFQPOPLGDLGSKSGTTALKVGCLQLNALITPAELDFRVHINSELMLGLH 387						
224	-----RELES-LRIQ---QROGNCP-----TNSEYWA--ALMELLREK 258						
388	QVIQDQLRETEENELRVOVNLNVEDOGEEDSYDILGRLDDIRMDDNEVROLLNWKD 447						
259	E-----ERTIALEADMTKWQKY--LEENV-----MRHFALDAAT 292						
448	KAEPHFLSLQHLLVRLNDYEARQPYKLIIECISQVLHKNGADPDFCKRLQIEGL 507						
293	VAAORDTTWISHP-----NTSYDTALEARQKEEETILMANRKCLDEMRICTHAQI 346						
508	IDQMDIKTKVEKSAKAAELEKKLDSELTARHILQVEMKME-----DFEQLQDQG-- 562						
347	IEDKAMIKVLQQRSKESKTECLSMCPAKSLSMISNAGSGLLHSHTLG--SPIMEE 404						
562	-EKDOL-----ISEKQIATE-----QLEAVWSQJTGVEVALIKE 597						
405	KRDKKSWKQSLGIGLGGDYRAEVVPSTS--PPVPSPTLSSAKHSKTCGSRDCSTQTERTGE 462						
598	LEDAKKEMASLSA-----AITVPPSVPSRAFPVPPAPL-----PGDSGT- 638						
463	SNKTAAVAPISVRPVAAATAAATAPATTTMTAACPVAAAAPA-----AAA 517						

Page 6

	Query Match	6.2%	Score 207.5;	DB 1;	Length 561;
	Best Local Similarity	22.1%	pred. No. 2.	3e-05;	
Matches	107;	Conservative	85;	Mismatches	157;
				Indels	135;
				Gaps	20
53	LQKVETEIQRVSSEAVNLVKSSKRRALEKAMRNKLEGEFRMHDENRDLR--LETA	109			
b	: : : : - : : : : : : : : : : : : : :				
148	VOEYRSRLNEKKDELDEEL--SNKKEELQR-LTEKIEKTKEKENUNKESTEKNSEISM	203			
110	NKQLAEKEYRGSE-----DTKTIOSOLFAKNIE-----SOREKEKEAEL	149			
b	:: : : : : : : : : : : : : : : : : :				
204	EELSEKEKEIAENKEELADALGELFDAETIDKKEAKVKDULTEKILDASRKHEALAKEF	263			
Y					
150	ATANSTNEODRRHLETRDQALISNAQKVYLE--EELKKQVVD-----KVEKMQ	198			
b	: : : : : : : : : : : : : : : : : : :				
264	AESOGYEE--KLADKHATLAGEAKRNADAEAGNSKELKLNEMAEIGISDDLQKRVKAE	320			
b					
199	QALIVQLOQAACEK-REOLEHRLRTLRELEFLESRIOORQNGCQPTNVSEYNAAL-MELLR	256			
b	: : : : : : : : : : : : : : : : : :				

events, identify potential therapeutic agents, assess effects of diet etc.

PS disclosure: Pages 53-58; 75pp; English.

The sequence is that of a mutant rat alpha-myosin heavy chain which was used in the development of transgenic mammals, specifically mice. They can be used as a model for studying congestive heart failure (CHF) or hypertrophic cardiomyopathy. Such animals are used to study molecular and cellular events associated with CHF, to identify compounds for treating CHF, and in evaluating effects of diet and exercise on CHF. Conditions associated with CHF that can be evaluated this way are dilated or hypertrophic cardiomyopathy; acute aortic regurgitation; tricuspid stenosis; constrictive pericarditis; acute infective endocarditis; ischaemic heart disease; hypertension; primary myocardial disease; valvular or pericardial disease; hyperthyroidism; anaemia; arteriovenous fistula; beri-beri and Paget's disease.

Sequence 186(AA);

QY	257	EKEERILALLEADM--KWEQKYLE--ENVMRHFALEDAATVAQORDTTVISHSPWNTSYD	311
Db	370	ELEEQUEVKLVEITAARKKEAEBLQAKAEGLEDF-----EAVKAEE-----	412
QY	312	TALEARIQKEEEILMANKRCLDMEGILIKTLHQIIEKDMVQLQ--ORSRKEPSKE	368
Db	412	-ALEAEIAKLKE-----DHQEVDALWALLADKEKMKLNQDOLDKRAKEEAMKNE	460
QY	369	OLSCMRPAKSLSMSISNAGSGLLSSHTIGSPIMEEKRDSDKSWKGSLIGLGGDYRAEYV	428
Db	461	OQMSQEERKALQAEELDQAKKEL-----	485
QY	429	PSTPSPVPPPSTPLSAHSKTSRDCSTOTERGESNSTAAYAPISYPA---PVAAATA	484
Db	486	KDMPNKVAP----QAEKGKANAGQAAPNQNQNAQANQAKNGNNLPSTGDKPVNPLLVA	540
QY	485	AAIT 488	
Db	541	SGLS 544	

RESULT	
ID	W54241
ID	W54241 standard; Protein: 1886 AA.
AC	W54241;
FT	17-AUG-1998 (first entry)
FT	Rattus norvegicus mutant alpha-myosin heavy chain.
FT	Action binding domain; alpha myosin heavy chain; bridging; mouse; transgenic mammal; congestive heart failure; study; treatment; diet; exercise; effects; identification; hypertrophic cardiomyopathy; dilated or hypertrophic cardiomyopathy; acute aortic regurgitation; tricuspid stenosis; constrictive pericarditis; hypertension; acute infective endocarditis; ischaemic heart disease; primary myocardial disease; valvular disease; pericardial disease; hyperthyroidism; anaemia; arteriovenous fistula; beri-beri; Rattus norvegicus; Pageer's disease; transgene.
OS	Synthetic.
OS	
FH	Location/Qualifiers
Region	403
/note	= "Arg403Gln mutation"

FT
PN W09813476-A1.
PD /note= "nonmyosin actin binding domain bridge"
PF 02-ADR-1998.
PE 26-SEP-1997; U17295.
PR 26-SEP-1996; US-026742.
PA (LEIN) LEINWAND LA.
PI VIKSTROM KL.
DR WPI; 98-220690/20.
N-PSB; V21518.
PT Transgenic mouse models for congestive heart failure and
hypertrophic cardio-myopathy - used to study molecular and cellular ar-

FT peptide 148...174
 FT /label= Hemagglutinin_epitope
 FT 175...2272
 FT /label= Residues_18-2116_of_NUMA
 FT 365...1864
 FT /label= Coiled_coil_region
 PN W09640917-A1.
 PD 19-DEC-1996.
 PF 07-JUN-1996; U09504.
 PR 07-JUN-1995; US-478408.
 PA (UVA) UNIV YALE.
 PI McPherson SMG, Snyder MP;
 DR WPI: 97-07270-07.
 DR N-PSDB; P77782.
 PT New nucleic acid encoding nuclear mitotic appts. interacting
 PT proteins - useful for modulating cell division and proliferation and
 PT in diagnosis.
 PS Claim 14; Page 28-36; 78pp; English.
 CC The sequences given in W21731-32 represent fusion proteins which contain
 CC NUMA (nuclear mitotic apparatus). The fusion proteins were used in
 CC the identification of NumA interacting proteins (NIP's) (see also
 CC W21729-30). Compounds which interfere with the interaction of NumA
 CC with a known NIP are used to modulate cell division and/or proliferation.
 CC Ab, raised conventionally using NIP-1 or -2 as immunogen, are used to
 CC detect NIP (or their complexes) and to block their activity for
 CC diagnostic or therapeutic use, e.g. to detect defective NumA or NIP
 CC which may be markers for aberrant (including malignant) cell growth
 CC (which can also be detected by nucleic acid sequencing). Also where
 CC malignancy is related to defects in NumA or NIP, it can be treated by
 CC administration of the appropriate functional protein.
 SQ Sequence 2272 AA;

Query Match 6.1%; Score 204; DB 1; Length 2272;
 Best Local Similarity 21.2%; Pred. No. 0.0002; Matches 101; Mismatches 82; Conservative 163; Indels 130; Gaps 17;
 Matches 101; Conservative 82; Mismatches 163; Indels 130; Gaps 17;
 QY 24 RAOQWELLSDENRULROELEGGCERKVARLQKVETIQRSEAYENLVSSSKRKEALERA 83
 Db 1156 RGQOBREBEVALTQERGRAGADLALEKAAR--AELEMRLQNALQEVRFATQLEALAH 1212
 QY 84 MRNILEG---EIRRNHDFN-----RDLERLFTANKOALAEKTYE--GS----- 122
 Db 1213 LTER-EGKQELAKURGLERAQIREKLELQLTQVQLKEOLAKRKEHASGSGAOSEAGR 1271
 QY 122 -----EDTRKTIISOLPAKNKNSOREEKELELATERSTN-----EDQ 159
 Db 1272 TEPPGPKPLEALRATEVSKLQOCQKQEQADSLERSLEAERASRAERSALETLOGOLEEK 1331
 Q. 160 RRHEIIRDQLSNQ-----AKVVKLEELKKQVYDVERK-- 197
 Db 1332 AQEQLGHSSOSALASARELAFAFRTKYQDHISKAEDEWKAQARGRGREAERNSSLISLEREV 1391
 QY 197 --MQLALVQ-----LQAAGCKRQELEHRRL-----TRLEREL 226
 Db 1392 SILRQVLEKEGEKELKLVMSKSEKSOKEERLQLQETASSSARAERSALREV 1451
 QY 227 ESLHLIQQRGNCQCTINVSNTAAALMELLREKEERILAEADMWKWEGYLE ENVMRF 285
 Db 1452 OSLRBEAEKQRVASEN-----LROELTSQAERAEELGOELKAWQEKFQKOALSTL 1503
 QY 286 ALDDAAATVAQDQTIVISH--SPRTSYDPALEARIKREEE-----ELMANIKC 332
 Db 1504 OLEHINSTQOLVSELLELPAPKHCQOQAEQAAEKHREELEOSKAQAGGLRAELRAQEL 1563
 QY 333 LDMMGRIKILHAQITKEKDAMIKYDQRSKREPSTEQISCMRPLSMSISNAGSG 388
 Db 1564 ---GELIPLRQKVAEQE---RPAQIAEKAASKAQAELQSMKKGJLAAENGIG 1612

Thu Jan 27 10:13:41 2000

us-09-332-063-2.rag

Db 2065 AEVOLRLHEAEKKHQALLDTNKOQEVEIQTYREKLSSKEECLISOKLEIDLKSSKEL 2124
 Qy 171 SNACAKVVKLVEELKKQY---YVDKV---EKMHQALVQLOACEKREQUEHLRTRL 222
 Db 2125 NNSIKATTOILEELKKTMDNLKVNLKENERAQGMKMLIKSKOLEEREKLQEL 2184
 Qy 223 ERLESLRIQQRCNGCOPTNSEWA - AALMELREKEERILALEADMKTWQEQYJEN 280
 Db 2185 S-OQLQAAEOKQYGTVMPTKVDPITTEIQLKELTLEEK----- TKEADYLDK 2232
 Qy 281 VMRHFAALDAATVAQDRTVTISHSPNTSYDTEALARIKEEEBLANKRCLDEMERIC 340
 Db 2233 C-----SLLSH-----KIEKAKIM-----LETOVA 2254
 Qy 341 TLHAQILEKDA--MIKVLOQRSRKERSKTEOLSCMRPAKSLMSISNAGSGLISHASTL 396
 Db 2255 HLCSQQSODRSRGSPPLGPVVRGSPSPISVTE-----KRESGQNKAQSKRQRSGI 2306
 Qy 397 TGSFIMEERKDDKSWKGSIGLILGGDYRAEYVSTPSVPSPSPPLUSAHSKTSRDC-STQ 456
 Db 307 -----WENG----GG-----PIPATPESFKSKKAVMSGIHPE 2337
 Db 457 TERGESNKTAAVAPISYPAPVAAATAAATATAATI-TTMVAAPVAAAAPAA 514
 Db 2338 DFGEGTE-----FEPEGIPEVVKGFADIPGTSIPSPYLRRWM----- 2376
 Qy 515 AAASPATAATAAVSPAAGOIPAMASVASAVAPSAAAAYOVAAPAPYAPA 574
 Db 2376 ATRNSP-RLAAOKLALSPLSLGKENLAES-----SIXTAGSRSQKVYVAQSPUDSGT 2428
 Qy 575 LVPVPPAPAAQASPAQTOQAPTSAPAVAPTPAPTPTPAVAAQAEVSPATG 625
 Db 2429 ILREP---TKSPV---NNLPERSPTDSPREGLRVKGRGVFPSPKAG 2470

RESULT 2

Sequence 1, Application US/08353700

Patent No. 599919
GENERAL INFORMATION:

APPLICANT: YEN, TIMOTHY J.

TITLE OF INVENTION: NUCLEIC ACID ENCODING A

TITLE OF INVENTION: TRANSIENTLY-EXPRESSED KINETOCHORE PROTEIN,
NUMBER OF SEQUENCES: 4CORRESPONDENCE ADDRESS:
ADDRESSEE: DANN, DORFMAN, HERRELL AND SKILLMANSTREET: 1601 MARKET STREET, SUITE 720
CITY: PHILADELPHIA
COUNTRY: USA
STATE: PA
ZIP: 19103-2307COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy diskOPERATING SYSTEM: IBM PC compatible
SOFTWARE: PC-DOS/MS-DOSCURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/353,700
FILING DATE: 09-DEC-1994CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: REED, JANET E.REGISTRATION NUMBER: 36,252
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 563-4100
TELEFAX: (215) 563-4044INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 3248 amino acids
TYPE: amino acid
STRANDEDNESS: single

TOPOLOGY: linear
MOLECULE TYPE: protein
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: HUMAN
US-08-353-700-1

Query Match 6.7%; Score 225; DB 1; Length 3248;
Best Local Similarity 21.4%; Pred. No. 1.1e-06; Matches 110; Mismatches 167; Indels 132; Gaps 21;
Matches 110; Conservative 106; Mishuffles 157; Index 132; Gaps 21;

Qy 20 ATVSRAQMVEILSDENRNLROLEGCEYKARLOK-----VETETORVSEAYE 68
 Db 2103 AAEYKEKEKELQTLQSSDVSSELKDQTHIQLQKOSLEQDSQALSLTKELENQIAQLNKEKE 2162
 Qy 69 NLVKSSSK-----REALEKARNKLGEIR-----RMHDNR--DLRE 104
 Db 2163 LLVKESSESQARLUSESDEYKLAVSKAALVERGEFALRLLSSTOEVHOLLRGTEKLV 2222
 Qy 105 RIETANKO-----LAEK-----BVEGSDTRITISQLEAKNEQSR---EKEKLERELAT 151
 Db 2223 RIEADEKKKHLTAEKLERERENDSLKDQVNVNLERELOMSPENOELVILDENAESKAVET 2282
 Qy 152 ARSTNEDORRKHIEIRDALSIWNAQVKVLEELKKQVYVYRVEKA-----QQA 200
 Db 2283 LKIQTEMARSKUFELDVLVIRSEKENLNLHQIQLEROGQISELDKLSSFLSLEEKEQA 2342
 Qy 201 LYOLQ-----AACKRE-----QLERRLRTRLE 225
 Db 2343 EIQIKEEKSTAVEMLQNLKESHHADLKGTVENLRELEARTNQEH-AALEANSKG 2461
 Db 2403 RARLEADEKKQVLCVQOLKESHHADLKGTVENLRELEARTNQEH-AALEANSKG 273
 Qy 274 OKYLEEN-----MRHFALDAA-----TVAQDRTVTISHSP-NTSYDTALEAR 317
 Db 2462 VEITKAKIEMGNTQSLSGLEDTVIRSEKENLNLHQIQLEROGQISELDKLSSFLSLEEKE 2520
 Qy 318 IOKEEERILMANKRCLDEMGEHKLTQHQITKLVQDRSR-KEPSITEQLC--MR 374
 Db 2520 EKEQEVQMEKSSTAME-MIOTQKELNRAVHALNDQBACKAREQNLSSQVCELE 2577
 Qy 375 PAKSLMSISNAGSGLISHSSPLTGSPIMEERKDD 409
 Db 2578 KAQLLOGLDEKKNYTVLOSSVKG--LIOEVEDGK 2610

RESULT 3
PCT-U95-1216-1
Sequence 1, Application PC/TUS9516216
GENERAL INFORMATION:
APPLICANT: Yen, Timothy J.
TITLE OF INVENTION: Nucleic Acid Encoding a transiently
Expressed Kinetochoore Protein, and Methods of Use
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dann, Dorfman, Herrell and Skillman
STREET: 1601 Market Street Suite 720
CITY: Philadelphia
COUNTRY: USA
ZIP: 19103-2307
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATOR SYSTEM: IBM PC compatible
SOFTWARE: PC-DOS/MS-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/U95/16216

FILING DATE:
CLASSIFICATION:
PRIORITY APPLICATION NUMBER: US 08/353,700
FILING DATE: 09-DEC-1995
ATTORNEY/AGENT INFORMATION:
NAME: Reed, Janet E.
REGISTRATION NUMBER: 36,252
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 563-4100
TELEFAX: (215) 563-4044
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 3248 amino acids
TYPE: amino acid
STRANDEDNESS: not relevant
TOPOLOGY: protein
MOLECULE TYPE: protein
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT;US95-16216-1

Query Match 6.7%; Score 225; DB 3; Length 3248;
Best Local Similarity 21.4%; Pred. No. 1.1e-06;
Matches 110; Conservative 106; Mismatches 167; Indels 132; Gaps 21;
QY 20 ATYSSRAQOEVILSDENRNRLQELLEGCVKVARQ-----VETEYRVSAYE 68
Db 2103 AEVKEKIELLQLTSLSD/SELLKDKTHILOEKLSLEKDSQALSLTKCELENQIAQNLKE 2162
QY 69 NLUVKSSK-----REAJEJKAMRKRLGEIR----RMHDFNR--DLRE 104
Db 2163. LLVKESESQQLRSLESDEYKLNVSKAELVALVERGAFARLSTSQQEVHOLRGTEKRV 2222
QY 105 RLETANKQ--LAEK---EVEGSDRTKTTSQLFAKNKESQR---EKEKLEALAT 151
Db 2223 RYERADEKKQLHIAEKKERERENDSLKDVKVENLERELOMSEENQEVILDAENSKAET 2282
QY 152 ARSTNEDORRHISERDQALNSAQAKVVKLEEELKKQKVYDVKEKM-----QQA 200
Db 2283 LKTOQEEMARSLIKFIELDVLTURSEKENLTQOLOEKQGQSLDCKLSSFKSLLKEQEA 2342
QY 201 IYVLOQ-----AACERRE-----OLEHHLRTRIREE 225
Db 2343 EIQIKEESKTAVEMLQNOLKELNEAVAALCGDQEIMKATEQSLDPPEEEHOLRNSTEKL 2402
Q1 226 LESLRIOORQNGC-QPTNVEYNAA-----MELLREKEERILALEADMWK 273
Db 2403 RARLLEADEKKQLCQLVQLQKESHHADLJGGRVNLERLEIARTNOH-AALEENSKGE 2461
QY 274 QKYLEENV-----MRHFALDAA-----TVAORDTVWISHSP--NTSYDTALEAR 317
Db 2462 VETLKAKIEGMQSLSRLGLELDVTIRSEKENLJNEQERERISELTINSFFENILQ-- 2520
Qy 318 IOKKEEEDILMANKKRCLOMGEKRKTLHQIERTADAMIKVLQQRSR-KEPSKIEQLSC-MR 374
Db 2520 -EKEQEVNERVKMSKSTANE-MLTQELNERVAHLNDQEAACKAKEQNLSSQFCLE 2577
Qy 375 PAKSLMSISNAGSGLSSHSTLGSPTIMEKKDD 409
Db 2578 KAQLQDGLDEAKNNYVQLOSSYKG--LIQEVEDGK 2610

RESULT 4
US-08-403-379A⁻¹
Sequence 51, Application US/08557309B
Patent No. 5916572
GENERAL INFORMATION:
APPLICANT: Reed, Janet E.
ADDRESS: 2103, 98104-7092
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:

CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, version #1.30
CURRENT APPLICATION DATA:
FILING DATE: 14-MAR-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 210121.406
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 262
MOLECULE TYPE: protein
US-08-403-379A-1

Query Match 6.4%; Score 213; DB 1; Length 262;
Best Local Similarity 48.4%; Pred. No. 2.8e-07; Matches 74; Conservative 9; Mismatches 54; Indels 16; Gaps 9;
QY 479 AAATAAAATATATATTTTAAAP--VAVAAAAP-AAAAPSPATAATAAVSPAA 534
Db 112 AAACAAAKQKAAKK-----AAAPSKSKKAKAIPAKAKAPAKAAPKAAPK 165
Qy 535 AGOIPAAASVSA-AAYAPSAAAAYVOPAIPAPWPAPLPVPAPAAQASAPQO 593
Db 166 AAAPAAPKAAAPAKAATAPAKAAAPAKTA-KAIPAKAAAPAKA-AAAPAKA-ATAPAKAA 222
QY 594 AFISAPAVAPVAPTPAPVAPVAPVAPVAPVAPVAPVAPVAPVAPVAP 626
Db 223 APAPKAATAPAKAAT-APAKA-AAAPAKAATAP 253

RESULT 5
US-08-557309B-51
Sequence 51, Application US/08557309B
Patent No. 5916572
GENERAL INFORMATION:
APPLICANT: Reed, Janet E.
ADDRESS: 2103, 98104-7092
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: Houghton, Raymond L.
TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DETECTION AND PREVENTION OF
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/557.309B
 FILING DATE: 14-NOV-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Maki, David J.
 REGISTRATION NUMBER: 31,392
 REFERENCE/DOCKET NUMBER: 210121.422
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4900
 TELEFAX: (206) 682-6031
 INFORMATION FOR SEQ ID NO: 51:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 263 amino acids
 TYPE: amino acid
 STRANDEDNESS: linear
 TOPOLOGY: linear
 US-08-557-309B-51

Query Match 6.4%; Score 213; DB 2; Length 263;
 Local Similarity 48.4%; Pred. No. 2.9e-07;
 Mismatches 54; Indels 16; Gaps 9;
 Matches 74; Conservative 9; Mismatches 54; Indels 16; Gaps 9;
 Mc-Matches 74; Conservative 9; Mismatches 54; Indels 16; Gaps 9;
 QY 479 AAATAAATATATATITTMVAAP--VAVAAAPA-AAAPSPATAATAAVSPAA 534
 Db 113 AAAAKAAKOKAAKK----AAPSGIKSKAAKAAAPAKAAAPAK 166
 QY 535 AGOIPAAASVASA-AAVPSAARAAVQVAPAPVAPVAPALVFPAPAAQASAPQTO 593
 Db 167 AAAAPAKAAKAAAPKAAATAPAKAAAPAKA-AAPAKAAAPAKA-ATAPAKAA 223
 QY 594 APTSAVAPTAAPTPTPAVQEVSPATGP 626
 Db 224 AAPKAATAPAKAT-APAKA-AAPAKAATAP 254
 RESULT 6
 US-08-929-414-1
 Sequence 1: Application US/08/29414
 Patent No. 594403
 GENERAL INFORMATION:
 APPLICANT: Reed, Steven G.
 APPLICANT: Haughton, Raymond
 APPLICANT: Skeily, Yasir A.W.
 TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DETECTION
 TITLE OF INVENTION: OF T. CRUZI INFECTION
 NUMBER OF SEQUENCES: 15
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: SEED and BERRY LLP
 STREET: 6300 Columbia Center, 701 Fifth Avenue
 CITY: Seattle
 STATE: Washington
 COUNTRY: USA
 ZIP: 98104-7092
 COMPUTER READABLE FORM:
 COMPUTER: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/557.309B
 FILING DATE: 14-NOV-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Maki, David J.
 REGISTRATION NUMBER: 31,392
 REFERENCE/DOCKET NUMBER: 210121.422
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4900
 TELEFAX: (206) 682-6031
 INFORMATION FOR SEQ ID NO: 54:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 219 amino acids
 TYPE: amino acid
 STRANDEDNESS: linear
 TOPOLOGY: linear
 US-08-557-309B-54

Query Match 6.4%; Score 213; DB 2; Length 262;
 Best local Similarity 48.4%; Pred. No. 2.8e-07;
 Matches 74; Conservative 9; Mismatches 54; Indels 16; Gaps 9;
 Mc-Matches 74; Conservative 9; Mismatches 54; Indels 16; Gaps 9;
 QY 479 AAATAAATATATITTMVAAP--VAVAAAPA-AAAPSPATAATAAVSPAA 534
 Db 112 AAAAKAAKOKAAKK----AAPSGIKSKAAKAAAPAKAAAPAK 166
 QY 535 AGOIPAAASVASA-AAVPSAARAAVQVAPAPVAPVAPALVFPAPAAQASAPQTO 593
 Db 166 AAAAPAKAAKAAAPKAAATAPAKAAAPAKA-AAPAKAAAPAKA-ATAPAKAA 223
 QY 594 APTSAVAPTAAPTPTPAVQEVSPATGP 626
 Db 223 AAPKAATAPAKAT-APAKA-AAPAKAATAP 253
 RESULT 7
 US-08-557-309B-54
 Sequence 54, Application US/08/557.309B
 Patent No. 5916572
 GENERAL INFORMATION:
 APPLICANT: Reed, Steven G.
 APPLICANT: Skeily, Yasir A.W.
 APPLICANT: Lodes, Michael J.
 APPLICANT: Houghton, Raymond L.
 TITLE OF INVENTION: COMPOUNDS AND METHODS FOR THE DETECTION AND
 NUMBER OF SEQUENCES: 69
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: SEED and BERRY LLP
 STREET: 6300 Columbia Center, 701 Fifth Avenue
 CITY: Seattle
 STATE: Washington
 COUNTRY: USA
 ZIP: 98104-7092
 COMPUTER READABLE FORM:
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/557.309B
 FILING DATE: 14-NOV-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Maki, David J.
 REGISTRATION NUMBER: 31,392
 REFERENCE/DOCKET NUMBER: 210121.422
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 622-4900
 TELEFAX: (206) 682-6031
 INFORMATION FOR SEQ ID NO: 54:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 219 amino acids
 TYPE: amino acid
 STRANDEDNESS: linear
 TOPOLOGY: linear
 US-08-557-309B-54

NAME: PITCHER ESO, EDMUND R
 REGISTRATION NUMBER: 27,849
 REFERENCE/DOCKET NUMBER: MTP-013
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 617/248-7100
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 2101 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-195-487-4

Query Match Similarity 6.1%; Score 204; DB 1; Length 2101;
 Best Local Similarity 22.3%; Pred. No. 1.5e-05; Matches 106; Mismatches 78; Indels 128; Gaps 19;

QY 24 RAQQMVEILSDENNRULQDLEGCEKVARLQVETORVSEAYENLVKSSKREALEKA 83
 Db 999 RGGQEREVARLQTQERGRAGAQLALEKAAR --AELEMRLQNALNEORVFATLOALHA 105

QY 84 MRNKLLEG--EIRRHMDFN-----RDLRERLETANQLEAEYE --GS----- 122
 Db 1056 LTER-EGKDQELAKLRGLEAAQIKELEELROTQVOLBKOLAKKEKEHASGSGRAEAGR 1114

QY 122 -----EDTRATISOLFANKNESOREKEKLELAELATARSTNEDORRHIEIRDOALSNA 173
 Db 1115 TEPTGPKLEALRAEVSKLEQOCOKQEQADSLSLEAERSRAE-----RDSALET 1167

QY 174 QAKVVKLLEKKQ-----VYVDVKVQMOQALVQOACER-REOLEHR--LR 219
 Db 1168 QGQLEEKQALGHQSOSALASAORBLAFTPQVODHSKADEWKAQVARGRQEERKNSLI 1227

QY 220 TRUEREL-----ESLRIQQQNC-----QPTNVSYYAA 250
 Db 1228 SSLEEVEVSLNROVLEKEGESEKELKLVMAESEKSQLEESACCRCRQPATVPELQAA 1287

QY 251 LM-----ELRE-----KEERTIALEADMWKWQKYLE-ENVMRHF 286
 Db 1288 LIICGRRCRASGREAEKORVASENRLQTSQARAEELQKAWQEKFQFQEQALSTLQ 1347

QY ~ 334 DMGRGIKTLHQIIEKDAMIKVQIQRSRKESPKTEQLSCMRPAKSLMSITSNAGSG 388
 Db ~ 407 --GELIPRQVAEQD--RTAQOLRAEKASYAEQISMKKAHGLAENRGLG 1455

RESULT 10
 PCT-US93-05160-4
 Sequence 4 Application PC/TUSS0306160

GENERAL INFORMATION:

APPLICANT:
 TITLE OF INVENTION: NOVEL MALIGNANT CELL TYPE MARKERS OF THE
 NUMBER OF SEQUENCES: 6
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: TESLA HUMWITZ & THIBEAULT
 STREET: 53 STATE STREET
 CITY: BOSTON
 STATE: MA
 COUNTRY: USA
 ZIP: 02109

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:

APPLICATION NUMBER: PCT-US93/061160
 FILING DATE: 19930621
 CLASSIFICATION:
 ATTORNEY/AGENT INFORMATION:
 NAME: PITCHER ESO, EDMUND R
 REGISTRATION NUMBER: 27,829
 REFERENCE/DOCKET NUMBER: MTP-013
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 617/248-7000
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 2101 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 TOPIC: US93-06160-4

Query Match Similarity 6.1%; Score 204; DB 3; Length 2101;
 Best Local Similarity 22.3%; Pred. No. 1.5e-05; Matches 106; Mismatches 78; Indels 128; Gaps 19;

QY 24 RAQQMVEILSDENNRULQDLEGCEKVARLQVETORVSEAYENLVKSSKREALEKA 83
 Db 999 RGGQEREVARLQTQERGRAGAQLALEKAAR --AELEMRLQNALNEORVFATLOALHA 105

QY 84 MRNKLLEG--EIRRHMDFN-----RDLRERLETANQLEAEYE --GS----- 122
 Db 1056 LTER-EGKDQELAKLRGLEAAQIKELEELROTQVOLBKOLAKKEKEHASGSGRAEAGR 1114

QY 122 -----EDTRATISOLFANKNESOREKEKLELAELATARSTNEDORRHIEIRDOALSNA 173
 Db 1115 TEPTGPKLEALRAEVSKLEQOCOKQEQADSLSLEAERSRAE-----RDSALET 1167

QY 174 QAKVVKLLEKKQ-----VYVDVKVQMOQALVQOACER-REOLEHR--LR 219
 Db 1168 QGQLEEKQALGHQSOSALASAORBLAFTPQVODHSKADEWKAQVARGRQEERKNSLI 1227

QY 220 TRUEREL-----ESLRIQQQNC-----QPTNVSYYAA 250
 Db 1228 SSLEEVEVSLNROVLEKEGESEKELKLVMAESEKSQLEESACCRCRQPATVPELQAA 1287

QY 251 LM-----ELRE-----KEERTIALEADMWKWQKYLE-ENVMRHF 286
 Db 1288 LIICGRRCRASGREAEKORVASENRLQTSQARAEELQKAWQEKFQFQEQALSTLQ 1347

QY ~ 287 LDAATAVVAQDTTVISH--SPNTSYDPALEAIIQKEEE-----EILMANKRCL 333
 Db ~ 334 DMGRGIKTLHQIIEKDAMIKVQIQRSRKESPKTEQLSCMRPAKSLMSITSNAGSG 388
 Db ~ 407 --GELIPRQVAEQD--RTAQOLRAEKASYAEQISMKKAHGLAENRGLG 1455

RESULT 11
 US-09-533-06A-2
 Sequence 2, Application US/08533306A
 Patent No. 5837457
 GENERAL INFORMATION:
 APPLICANT: Liu, Pu
 APPLICANT: Collins, Francis S.
 APPLICANT: Siciliano, Michael J.
 APPLICANT: Claxton, David
 TITLE OF INVENTION: Markers for Detection of Chromosome 16
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Harness, Dickey & Pierce, P.L.C.
 STREET: P.O. Box 828
 CITY: Bloomfield Hills
 STATE: MI

COUNTRY: USA
 ZIP: 48303
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US-08/533-306A
 FILING DATE: September 25, 1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Smith, Deann F.
 REGISTRATION NUMBER: 36683
 REFERENCE/DOCKET NUMBER: 2115-00869COB
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (810) 641-1600
 TELEFAX: (810) 641-0270
 FORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 576 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-533-306A-2

Query Match 6.1%; Score 203; DB 2; Length 576;
 Best Local Similarity 23.4%; Pred. No. 3.5e-06;
 Matches 101; Conservative 74; Mismatches 150; Indels 106; Gaps 16;

QY 30 EILSDENRUR---QELEGCVKVARLQKVETE----IQRVSEAVENLVKSSKREA 79
 Db 192 ELQASEDAKLRLVENMQLAQFERDQADNEKEKRQLRQLQRLQRYHEVETELEDERNERA 251

QY 80 LEKAMRNKLEGEIRRHMDFNRDLRERLETANKOLAE----KEYEGS-EDTRKTIISQLFA 133
 Db 252 LAARKKKLEGDLKOLELQADSALKGREAKIKQLRKQLQAMKDQRELEDARASDEIRFA 311

QY 134 KNKKSQR-----EKEKLEALATA--RSTNEDQRH 162
 Db 312 TAKENEKKAKSLEADMQLQEDLAAERARKROADLEKEELAELASSLGRNAQDEKRR 371

QY 163 IEIRDQALSNQAQKVVKLEELKKQ---VVVDKVERMQALVOL--QACER-REOLE 215
 Db 372 LE-----+ARIAQLEEELEPQMGMEAMSRSVRKATQOQLSNELATERSTAQRN 421

QY 216 HRLRTRLERELESIRIQRQNGCOPNTSEYNAALMELIREKERLILAEADMTKWBOK 275
 Db 422 ESARQOLERONKELR-----SKLHEMEGAVSKRF---KSTIAALEAKIAQ--- 464

QY 276 YLEENVMRHFALDAATVAQARDTIVISHSPNTSYDTALEARIQKEEFLMANKRCLDM 335
 Db 464 -LEFOVEQEAREKQATSKLKOK-----DKKLEILQLQVEDERKMAEQYKEGA 510

QY 336 E--GRIKTLHQIIEKDMIKVLIQRSRKEPSKTEQLSCMRPKSLMSISNAGGLUSH 392
 Db 511 EKGNAVRKQLKROLEEEAESQRINANRKLQRELDEATESNEA-----MGREVNAL 562

QY 393 SSTLGTGSPIME 4C3
 Db 563 KSKLRGPPQOE 573

TITLE OF INVENTION: Markers for Detection of Chromosome 16
 NUMBER OF SEQUENCES: 14
 CORRESPONDENCE ADDRESS: Rearrangements
 ADDRESSEE: Harness, Dickey & Pierce, P.L.C.
 STREET: P.O. Box 828
 CITY: Bloomfield Hills
 STATE: MI
 COUNTRY: USA
 ZIP: 48303
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US-08/533-306A
 FILING DATE: September 25, 1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Smith, Deann F.
 REGISTRATION NUMBER: 36683
 REFERENCE/DOCKET NUMBER: 2115-00869COB
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (810) 641-1600
 TELEFAX: (810) 641-0270
 FORMATION FOR SEQ ID NO: 2:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 885 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-533-306A-4

Query Match 6.1%; Score 203; DB 2; Length 885;
 Best Local Similarity 23.4%; Pred. No. 6e-06;
 Matches 101; Conservative 74; Mismatches 150; Indels 106; Gaps 16;

QY 30 EILSDENRUR---QELEGCVKVARLQKVETE----IQRVSEAVENLVKSSKREA 79
 Db 501 ELQASEDAKLRLVENMQLAQFERDQADNEKEKRQLRQLQRLQRYHEVETELEDERNERA 560

QY 80 LEKAMRNKLEGEIRRHMDFNRDLRERLETANKOLAE----KEYEGS-EDTRKTIISQLFA 133
 Db 561 LAARKKKLEGDLKOLELQADSALKGREAKIKQLRKQLQAMKDQRELEDARASDEIRFA 620

QY 134 KNKKSQR-----EKEKLEALATA--RSTNEDQRH 162
 Db 621 TAKENEKKAKSLEADMQLQEDLAAERARKROADLEKEELAELASSLGRNAQDEKRR 680

QY 163 IEIRDQALSNQAQKVVKLEELKKQ---VVVDKVERMQALVOL--QACER-REOLE 215
 Db 681 LE-----+ARIAQLEEELEPQMGMEAMSRSVRKATQOQLSNELATERSTAQRN 730

QY 216 HRLRTRLERELESIRIQRQNGCOPNTSEYNAALMELIREKERLILAEADMTKWBOK 275
 Db 731 ESARQOLERONKELR-----SKLHEMEGAVSKRF---KSTIAALEAKIAQ--- 773

QY 276 YLEENVMRHFALDAATVAQARDTIVISHSPNTSYDTALEARIQKEEFLMANKRCLDM 335
 Db 773 -LEFOVEQEAREKQATSKLKOK-----DKKLEILQLQVEDERKMAEQYKEGA 819

QY 336 E--GRIKTLHQIIEKDMIKVLIQRSRKEPSKTEQLSCMRPKSLMSISNAGGLUSH 392
 Db 820 EKGNAVRKQLKROLEEEAESQRINANRKLQRELDEATESNEA-----MGREVNAL 871

QY 393 SSTLGTGSPIME 403
 Db 872 KSKLRGPPQOE 882

RESULT 12
 US-08-533-306A-4
 Sequence 4, Application US-08/533-306A
 Patent No. 5837457
 GENERAL INFORMATION:
 APPLICANT: Liu, Pu
 APPLICANT: Collins, Francis S.
 APPLICANT: Siciliano, Michael J.
 APPLICANT: Claxton, David

US-08-533-306A-6

Sequence 6, Application US/08533306A

Patent No. 5837457

GENERAL INFORMATION:

APPLICANT: Liu, Pu

APPLICANT: Collins, Francis S.

APPLICANT: Siciliano, Michael J.

TITLE OF INVENTION: Markers for Detection of Chromosome 16

TITLE OF INVENTION: Rearrangements

NUMBER OF SEQUENCES: 14

CORRESPONDENCE ADDRESS:

ADDRESSEE: Harness, Dickey & Pierce, P.L.C.

STREET: P.O. Box 828

CITY: Bloomfield Hills

STATE: MI

COUNTRY: USA

ZIP: 48303

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

OPERATING SYSTEM: PC-DOS/MS-DOS

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08533-306A

FILING DATE: September 25, 1995

ATTORNEY/AGENT INFORMATION:

NAME: Smith, Deann F.

REGISTRATION NUMBER: 36683

REFERENCE/DOCKET NUMBER: 2115-00869G0B

TELECOMMUNICATION INFORMATION:

TELEPHONE: (810) 641-1600

TELEFAX: (810) 641-0270

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 816 amino acids

TYPE: amino acid

TOPOLGY: linear

MOLECULE TYPE: protein

US-08-533-306A-6

Query Match 6.1%; Score 203; DB 2; Length 816;

Matches 101; Conservative 74; Mismatches 150; Indels 106; Gaps 16;

Oy. 30 EILSDENRUR---QELEGCEYKARLQVETE---IQRVSEAVENLYKSSKREA 79

Db 432 EIQASEDAKLRLVNMQALKGOFERDLDORDEONEKEKKRQLQHVEYETELEDERNERA 491

Oy 80 LEKAMRNKLEGETRMHDNFDLRLERLETANKOLAE---KEYEGS-EDTRKTISOLF 133

Db 492 LAAAKKKLEGDLQDLEQDASAIKGREEAKIKQRLQAOQMDFORELEDAKRSDEIF 551

Oy 134 KNNESQR-----EKENLEALATA---RSTNEDORRH 162

Db 552 TAKENEKKAKSLADELMLQDQELAERARKQADLEKEELAELSSGRUNQDEKRR 611

Oy 163 IEIPDQLNSNAQVKVKEELKKQ---WYDVKEMQALVOL-QACEK-RQLE 215

Db 612 LE-----AKIAQEELEEEQEGNNEAMSDRVKAQDQELAELSTERAQKN 661

Oy 216 HRLRTLRELESRIQORQNGCOPTINSEYNAALMELLREKEERILAELADMTRWEQK 275

Db 662 ESARQOLERKONKER-----SKLHEMEGAVKSRF---KSTIAALEAKIAQ--- 704

Oy 276 YLENVNRFLDAAATQAQROJTVISHSPNTSYDALEEARQKEERILAELADMTRWEQK 335

Db 704 -LEQVEGEAREKAAKTSLKQ-----DKKLKEILLOVEDERKMAOEYEQ 750

Oy 336 E---GRIKTLHAQIIEKAMIKYUQSRKPSKTEQLSCLMRPAKSLMSISNAGSGL 392

| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

Db 751 EKGNAVRKVKQROLEAEESQRINANRKQRELDEATESNEA-----MGREYNAL 802

Oy 393 SSTJLGSPINE 403

Db 803 KSKLRGPQQE 813

RESULT 14

US-08-742-923A-2

; Sequence 2, Application US/08742923A

; Patent No. 5869611

; GENERAL INFORMATION:

; APPLICANT: Liu, Pu

; APPLICANT: Collins, Francis S.

; APPLICANT: Siciliano, Michael J.

; TITLE OF INVENTION: Markers for Detection of Chromosome 16

; TITLE OF INVENTION: Rearrangements

; NUMBER OF SEQUENCES: 14

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Harness, Dickey & Pierce, P.L.C.

; STREET: P.O. Box 828

; CITY: Bloomfield Hills

; STATE: MI

; COUNTRY: USA

; ZIP: 48303

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08-742-923A

; FILING DATE: No. 5869611ember 1, 1996

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Smith, Deann F.

; REGISTRATION NUMBER: 36683

; REFERENCE/DOCKET NUMBER: 2115-00869DVC

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (810) 641-1600

; TELEFAX: (810) 641-0270

; INFORMTION FOR SEQ ID NO: 2:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 576 amino acids

; TYPE: amino acid

; TOPOLOGY: linear

; MOLECULE TYPE: protein

; US-08-742-923A-2

Query Match 6.1%; Score 203; DB 2; Length 576;

Best Local Similarity 23.4%; Pred. No. 3 5e-05;

Matches 101; Conservative 74; Mismatches 150; Indels 106; Gaps 16;

Oy 30 EILSDENRUR---QELEGCEYKARLQVETE---IQRVSEAVENLYKSSKREA 79

Db 192 EIQASEDAKLRLVNMQALKGOFERDLDORDEONEKEKKRQLQHVEYETELEDERNERA 491

Oy 30 LEKAMRNKLEGETRMHDNFDLRLERLETANKOLAE---KEYEGS-EDTRKTISOLF 133

Db 134 KNNESQR-----EKENLEALATA---RSTNEDORRH 162

Oy 252 LAAAKKKLEGDLQDLEQDASAIKGREEAKIKQRLQAOQMDFORELEDAKRSDEIF 551

Db 134 KNNESQR-----EKENLEALATA---RSTNEDORRH 162

Oy 312 TAKENEKKAKSLADELMLQDQELAERARKQADLEKEELAELSSGRUNQDEKRR 611

Oy 163 IEIPDQLNSNAQVKVKEELKKQ---WYDVKEMQALVOL-QACEK-RQLE 215

Db 372 LE-----AKIAQEELEEEQEGNNEAMSDRVKAQDQELAELSTERAQKN 421

Oy 216 HRLRTLRELESRIQORQNGCOPTINSEYNAALMELLREKEERILAELADMTRWEQK 275

| : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | :

